N/A
Manufactured by A2A Integrated Pharmaceuticals
15,363 FDA adverse event reports analyzed
Last updated: 2026-04-14
RANOLAZINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by A2A Integrated Pharmaceuticals. The most commonly reported adverse reactions for RANOLAZINE include DEATH, MYOCARDIAL INFARCTION, CHEST PAIN, ANGINA PECTORIS, STENT PLACEMENT. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RANOLAZINE.
Out of 10,011 classified reports for RANOLAZINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 15,363 FDA FAERS reports that mention RANOLAZINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DEATH, MYOCARDIAL INFARCTION, CHEST PAIN, ANGINA PECTORIS, STENT PLACEMENT, DYSPNOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list A2A Integrated Pharmaceuticals in connection with RANOLAZINE. Always verify the specific product and NDC with your pharmacist.